Second-line chemotherapy in malignant pleural mesothelioma (MPM) Source: Eur Respir J 2002; 20: Suppl. 38, 273s Year: 2002
Systemic treatment of malignant mesothelioma Source: Eur Respir Mon; 2009: 44: 419–434 Year: 2009
Systemic therapy 1 in malignant pleural mesothelioma: chemotherapy Source: ERS Online Course 2020: Calendar sheets in malignant pleural diseases Year: 2020
Chemotherapy for treatment of malignant pleural mesothelioma Source: Eur Respir J 2004; 24: Suppl. 48, 526s Year: 2004
Evaluation of response to chemotherapy for malignant pleural mesothelioma and suggestion of a new method Source: Eur Respir J 2002; 20: Suppl. 38, 272s Year: 2002
Treatment of malignant pleural mesothelioma with caelyx: few responses but good survival Source: Eur Respir J 2004; 24: Suppl. 48, 526s Year: 2004
Bevacizumab-targeted therapy for malignant pleural mesothelioma Source: International Congress 2017 – Malignant pleural effusion management in 2017: a review of recent RCTs Year: 2017
Multimodal therapy in malignant pleural mesothelioma (MPM) Source: Eur Respir J 2002; 20: Suppl. 38, 187s Year: 2002
Three dimensional evaluation of chemotherapy response in malign pleural mesothelioma Source: Eur Respir J 2007; 30: Suppl. 51, 754s Year: 2007
The therapeutic efficacy of troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010
Polychemotherapy experience in pleural mesothelioma with or without pemetrexed Source: Annual Congress 2009 - Pleural and mediastinal diseases Year: 2009
Effects of cisplatin and pemetrexed on 3D phenotypes of benign mesothelial and malignant pleural mesothelioma cells Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma Year: 2018
Efficacious pleurodesis with OK-432 and doxorubicin against malignant pleural effusions Source: Eur Respir J 2004; 24: 263-266 Year: 2004
Systemic therapy 2 in malignant pleural mesothelioma: immuno- & targeted therapy Source: ERS Online Course 2020: Calendar sheets in malignant pleural diseases Year: 2020
Is there any advantage of chemotherapy on survival of patients with diffuse malignant pleural mesothelioma? Source: Eur Respir J 2003; 22: Suppl. 45, 29s Year: 2003
Elevated circulating activin A levels in malignant pleural mesothelioma patients are related to cancer cachexia and poor response to platinum-based chemotherapy Source: International Congress 2019 – Brain Metastasis and Malignant pleural effusion: improving our understanding Year: 2019
Multimodality therapy for malignant pleural mesothelioma Source: Eur Respir J 2004; 24: Suppl. 48, 526s Year: 2004
Prognostic indexes for the efficacy of intrapleural instillation of bleomycin, alpha2-interferon and gamma-interferon in the control of malignant pleural effusions Source: Eur Respir J 2001; 18: Suppl. 33, 397s Year: 2001
Treatment of malignant pleural mesothelioma with combination of carboplatin, caelyx, and gemzitabine: the CCG study of the Nordic mesothelioma group Source: Eur Respir J 2004; 24: Suppl. 48, 526s Year: 2004
Role of surgery and of radiotherapy in malignant pleural mesothelioma Source: ERS Online Course 2020: Calendar sheets in malignant pleural diseases Year: 2020